Table 4.

AddiQoL-30 in Group A and B at baseline and 6 months after switching from conventional hydrocortisone treatment (IR-HC) to dual-release hydrocortisone (DR-HC).

	GROUP A		P-value (Group A DR-HC vs IR-HC)		GROUP B		P-value (Group B DR-HC vs IR-HC)
	QoL IR-HC(pg/ml)	QoL DR-HC(pg/ml)			QoL IR-HC(pg/ml)	QoL DR-HC(pg/ml)
Patient 1	88	96		Patient 1	94	99
Patient 2	85	98		Patient 2	99	95
Patient 3	92	107		Patient 3	88	94
Patient 4	96	110		Patient 4	96	100
Patient 5	92	102		Patient 5	90	94
Patient 6	96	108		Patient 6	94	100
Patient 7	86	95		Patient 7	98	104
Patient 8	91	98		Patient 8	99	102
Patient 9	89	96		Patient 9	82	89
Patient 10	94	102		Patient 10	90	96
Median	91 (87–94)	100 (96–107)	0.005	Median	94 (89–98)	98 (94–100)	0.004